ImmunoCellular Therapeutics, Ltd. announced today that the first patient in the phase I clinical trial of ICT-121, a cancer vaccine targeting recurrent glioblastoma multiforme , has received the vaccine.
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131223005794&newsLang=en&ndmConfigId=1000639&vnsId=41
http://www.businesswire.com/portal/site/topix/index.jsp?ndmViewId=news_view&newsId=20131223005794&newsLang=en&ndmConfigId=1000639&vnsId=41
No comments:
Post a Comment